LECT2 amyloidosis
LECT2 Amyloidosis[edit | edit source]
LECT2 amyloidosis is a form of amyloidosis characterized by the deposition of leukocyte cell-derived chemotaxin 2 (LECT2) protein in various tissues, leading to organ dysfunction. It is a rare condition that primarily affects the kidney, but can also involve other organs such as the liver and spleen.
Pathophysiology[edit | edit source]
LECT2 is a protein that is normally produced by the liver and plays a role in immune response and inflammation. In LECT2 amyloidosis, the LECT2 protein misfolds and aggregates into amyloid fibrils, which are deposited in tissues. This deposition disrupts normal tissue architecture and function, leading to organ damage.
Clinical Presentation[edit | edit source]
Patients with LECT2 amyloidosis often present with symptoms related to kidney dysfunction, such as proteinuria, edema, and hypertension. Some patients may also exhibit liver dysfunction or splenomegaly. The disease is often diagnosed in older adults and has been reported more frequently in individuals of Hispanic descent.
Diagnosis[edit | edit source]
The diagnosis of LECT2 amyloidosis is confirmed by biopsy of affected tissue, typically the kidney, showing amyloid deposits. These deposits are identified using Congo red staining, which reveals apple-green birefringence under polarized light. Immunohistochemistry or mass spectrometry can be used to specifically identify LECT2 as the amyloid protein.
Treatment[edit | edit source]
There is currently no specific treatment for LECT2 amyloidosis. Management focuses on controlling symptoms and complications, such as hypertension and chronic kidney disease. In some cases, kidney transplantation may be considered for patients with end-stage renal disease.
Prognosis[edit | edit source]
The prognosis of LECT2 amyloidosis varies depending on the extent of organ involvement and the patient's overall health. Kidney involvement often leads to progressive renal failure, which can significantly impact survival and quality of life.
Related Pages[edit | edit source]
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
